[{"id":"d22eb9bd-e761-411a-be69-a4044681ba61","acronym":"","url":"https://clinicaltrials.gov/study/NCT06237400","created_at":"2024-02-01T16:21:14.430Z","updated_at":"2024-07-02T16:35:21.354Z","phase":"Phase 1/2","brief_title":"A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.","source_id_and_acronym":"NCT06237400","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZG19018"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-01"}]